Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cifurtilimab (SEA-CD40) Combinations in Advanced Melanoma and NSCLC
NCT04993677Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of SEA-CD40 in melanoma, non-small cell lung cancer (NSCLC), sponsored by Seagen Inc.. Started Oct 2021; status: completed.
02
Drugs
SEA-CD40
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04993677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993677.